Indonesia Conference Directory

Background: The highest case of malaria in NTT Province is Lembata District. The use of Artemisinine Combination Therapy (ACT) combined with Primakuin (PQ) in the treatment of vivax malaria aims to prevent treatment failure. The development of drug resistance and recurrence has been reported in some areas by Plasmodium falciparum. For Plasmodium vivaks no resistance has been reported to the given regimen. Evaluation of the efficacy of Dihydroartemisinin piperaquine (DHP) combined with Primakuin (PQ) has never been done. Aims: To evaluate the efficacy and side effects of DHP + PQ in the treatment of Vivax malaria in Wulandoni District, Lembata District. Methods: The subjects were vivaks malaria patients who met the inclusion criteria as stated in the WHO antimalarial drug resistance test. Clinical manifestations and side effects are monitored during the evaluation. Results: A total of 52 respondents followed the study. The age of the patients involved ranged from 2 to 76 years consisting of toddlers, children, productive and elderly (≥ 46 years). From the Mann-Whitney test results obtained p value <0.05 is a group of toddlers with productive age, a group of toddlers with old age, children with productive age and productive age with old age can be concluded there are differences in parasite density between these groups. Conclusion: There was a treatment failure as evidenced by blood tests found parasites at H3 were caused by the patient not taking medication completely. Clinical symptoms of vivax malaria patients are fever, chills and sweating accompanied by additional symptoms such as nausea, vomiting, diarrhea, headache, anorexia, aches and coughs. Side effects of DHP + PQ drugs are still in the mild category. Parasitological and clinical conditions and age have no relationship at all.